Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1644 1671
This examiner grants 50% of resolved cases
Chun Wu Dahle, in Tech Center 1600 and Art Unit 1641, has 664 resolved cases. Her allowance rate is 50.2%, and the median days to allowance is 1439. The interview lift of 51.2% is high, suggesting that interviews are important for success in her docket. This 51.2% lift can increase the 50.2% baseline allowance rate, making it a strategy for practitioners.
Applicants should be prepared for a 1439-day timeline and use interviews to navigate the 664 resolved cases she has handled. The 51.2% lift is an indicator that direct engagement is rewarded in Art Unit 1641. Given the 50.2% allowance rate and the 1439-day median pendency, a proactive interview approach is a way to secure a grant. This data provides a roadmap for managing applications in Tech Center 1600. These figures are the primary benchmarks for her assigned applications.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17615949 | ANTI-TNF ANTIBODY COMPOSITIONS, AND METHODS FOR THE TREATMENT OF PSORIATIC ARTHRITIS | Final Rejection | Janssen Biotech, Inc. |
| 18013864 | METHODS TO GLYCOENGINEER PROTEINS | Final Rejection | THE JOHNS HOPKINS UNIVERSITY |
| 18249708 | INJECTABLE HYDROGELS FOR ADOPTIVE CELL THERAPY | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17672346 | FCRN ANTAGONISTS AND METHODS OF USE | Final Rejection | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 17437448 | ANTI-IL-6 RECEPTOR ANTIBODY-CONTAINING INHIBITOR FOR INHIBITING DETERIORATION OF BBB FUNCTION | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 18033907 | GENETICALLY ENGINEERED ANTIGEN-SPECIFIC NATURAL KILLER CELLS FOR IN SITU SYNTHESIS OF PROTEINS | Final Rejection | SRI International |
| 18542918 | TREATMENT OF AUTOIMMUNE DISEASE | Non-Final OA | AstraZeneca AB |
| 18581959 | COMBINATIONS AND USES THEREOF | Non-Final OA | Incyte Corporation |
| 18411350 | COMBINATIONS AND USES THEREOF | Non-Final OA | Incyte Corporation |
| 17997171 | TREATMENT AND PREVENTION OF ALLOREACTIVITY USING VIRUS-SPECIFIC IMMUNE CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS | Final Rejection | Baylor College of Medicine |
| 18035894 | ANTIBODY-BASED CONJUGATE FOR ENHANCING THERAPEUTIC EFFECT OF TARGETED THERAPEUTIC AGENT | Non-Final OA | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18269257 | Method for Measuring Target Antigen, and Insoluble Particles and Kit for Target Antigen Measurement Used Therein | Final Rejection | Denka Company Limited |
| 18245239 | IMMUNOGENIC PRODUCT COMPRISING AN IgE FRAGMENT FOR TREATING IgE-MEDIATED INFLAMMATORY DISORDERS | Non-Final OA | INSTITUT PASTEUR |
| 18018400 | ENGINEERED MULTI-SPECIFIC ANTIBODIES AND RELATED METHODS OF USE AND MANUFACTURE | Non-Final OA | Gritstone bio, Inc. |
| 18415031 | HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE | Non-Final OA | Viela Bio, Inc. |
| 18303303 | USE OF AN ANTI-CD19 ANTIBODY TO TREAT AUTOIMMUNE DISEASE | Final Rejection | Viela Bio, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy